From: Medulloblastoma: clinicopathological parameters, risk stratification, and survival analysis of immunohistochemically validated molecular subgroups
Mean (months)
95% CI
Median (months)
% 1 year
% 2 year (end of study)
Overall survival (OS)
19.1
17.1-21.1
24
77.5%
50%
Progression-free survival (PFS)
15.83
13.6-18.1
17
65%
27.5%